Novo Nordisk and Eli Lilly announced its Q3 financial results, and the GLP-1 revenues were unbeatable, and it continued to soar on the road becoming a phenomenal product.

 

Novo Nordisk's total revenue in the first three quarters was 166.398 billion Danish kroner, a year-on-year increase of 29%. Among them, Semaglutide Injection, Wegovy, a once-a-week injection for long-term weight management, with sales of DKK 21.729 billion and a year-on-year increase of 481%; and Rybelsus, taken orally, with sales of DKK 12.84 billion.

 

Obesity is not only an independent disease, but also an important cause of many chronic diseases such as cardiovascular and type I diabetes, becoming a public health focus. With the increase in the obesity rate of the population year by year, the market scale of obesity treatment, hypoglycemic and weight loss drugs is also expanding continuously in China with a huge market space. At present, GLP-1 drugs have achieved positive results in clinical studies such as bariatric indications, cardiovascular, chronic kidney diseases. The application prospects of drugs are gradually becoming clear.

 

The market for GLP-1 weight-loss drugs has exploded, and about to reach a number of 100 billion US dollars, helping Eli Lilly and Novo Nordisk to become the top three pharmaceutical companies in term of stock market value in the world. The U.S. capital market highly recognizes the explosive growth of GLP-1, Novo Nordisk's semaglutide 

and Eli Lilly's tirzepatide, which are expected to exceed annually $20 billion and $4.5 billion respectively, helping Eli Lilly's a stock market value of $500 billion and Novo Nordisk's $400 billion.

 

The domestic market is about to explode, and a number of products have been launched or in late-stage clinical trials. According to the product type and R&D progress, as well as considering the sales capacity, those are clustered as:

1) The new drugs of GLP-1 for weight loss, along with a complete pipeline: U.S. stock focus - Eli Lilly, Novo Nordisk, etc.; Domestic focus: Innovent Biologics, Huadong Pharmaceutical, CSPC Pharmaceutical Group (Xinnuowei), Hengrui Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, etc.;

2) Semaglutide compound patent to be expired in China in 2026, and companies with fast progress are concerned: Livzon Pharmaceutical Group Inc., Federal Pharmaceutical, Sihuan Pharmaceutical and Zhifei Biotechnology.

 

1.Novo nordisk

2.ELI Lilly